Polyclinique d'oncologie de Gentilly, Nancy, France Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2014
NCT03761225
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Polyclinique d'oncologie de Gentilly, Nancy, France | Research and Innovation Department, Nancy University Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

enoxaparin (lovenox) (1 trial)

Drugs in Phase 3 Trials (3)

docetaxel (taxotere) (1 trial)

masitinib (1 trial)

prednisone (meticorten) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Embolism (Phase 4)

Prostatic Neoplasms (Phase 3)

Pulmonary Embolism (Phase 4)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Venous Thromboembolism (Phase 4)

Venous Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4